<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332238</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0999</org_study_id>
    <nct_id>NCT03332238</nct_id>
  </id_info>
  <brief_title>Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears</brief_title>
  <official_title>A Phase II Study to Evaluate Autologous Stromal Vascular Fraction Cell Therapy to Improve the Repair of Chronically Rotator Cuff Tears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopedic Research and Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rotator cuff disease is one of the most prevalent musculoskeletal conditions across the
      world. Patients with chronic rotator cuff tears often have substantial muscle atrophy and
      fatty infiltration. Surgical repair of the tear does not reverse the atrophy, and many
      patients continue to experience weakness, pain, and a persistent reduction in the quality of
      life. An important limitation in our ability to successfully rehabilitate these injuries
      postoperatively and return patients to normal function has to do with the poor quality of the
      muscle and tendon after rotator cuff repair. The stromal vascular fraction (SVF) of
      subcutaneous adipose tissue is highly enriched with cells (SVFCs) that can both directly
      participate in tissue regeneration by differentiating into myogenic and tenogenic cells, and
      indirectly by secreting growth factors and small molecules which activate pathways associated
      with healthy tissue regeneration. High numbers of autologous SVFCs can be isolated using the
      cost-effective, intraoperative Icellator (Tissue Genesis, Honolulu, HI) point-of-care system.
      This clinical trial will be determine if the use of SVFCs can enhance outcomes for patients
      who are undergoing surgical repair of a torn supraspinatus rotator cuff.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in scapular plane abduction strength from baseline, and additional isometric, isokinetic strength measurements to assess supraspinatus function.</measure>
    <time_frame>2 weeks prior to surgery, 6 months after surgery, 12 months after surgery, 24 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Penn Shoulder score, ASES score and Short Form Global Health scale (PROMIS-SF) from baseline (range 0 minimum to 30 maximum)</measure>
    <time_frame>2 weeks prior to surgery, 6 weeks after surgery, 6 months after surgery, 12 months after surgery, 24 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in supraspinatus muscle stiffness from baseline, measured by ultrasound shear wave elastrography</measure>
    <time_frame>1 month prior to surgery, 6 months after surgery, 24 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatty infiltration from baseline, measured by magnetic resonance imaging</measure>
    <time_frame>1 month prior to surgery, 6 months after surgery, 24 months after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Rotator Cuff Tear</condition>
  <condition>Muscle Atrophy</condition>
  <condition>Tendon Tear</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive an injection of vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cell Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an injection of stromal vascular fraction material suspended in vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Autologous Stomal Vascular Fraction Material</intervention_name>
    <description>Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™</description>
    <arm_group_label>Cell Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ringer's solution</intervention_name>
    <description>Ringer's solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Age 45-65 years old at the time of enrollment

          -  Full-thickness supraspinatus tendon tear with endon retraction ≤ 3 cm

          -  Magnetic resonance imaging Goutallier score ≤ grade 2

          -  Completed at least 6 weeks of standard physical therapy but continue to have pain and
             limited function (failed physical therapy)

          -  Sufficient subcutaneous abdominal adipose tissue to allow the recovery of 60-120cc of
             lipoaspirate

          -  Must pass standard of care blood work screening

        Exclusion Criteria:

          -  Any tears of any cuff tendon other than the supraspinatus

          -  Magnetic resonance imaging Goutallier scores ≥ 3

          -  Frank signs of glenohumeral osteoarthritis on magnetic resonance imaging

          -  A history of previous rotator cuff repair

          -  A history of upper extremity fracture or other moderate to severe upper extremity
             trauma

          -  A BMI &lt; 20 or &gt; 35

          -  Pregnant or breast feeding

          -  Premenopausal women who are not using contraception

          -  Previous abdominal liposuction or any major open abdominal surgery

          -  Type I or type II diabetes, or glycated hemoglobin (hemoglobin A1C) values &gt; 6.5 or
             other metabolic disorders

          -  Hypercholesterolemia (total cholesterol ≥240mg/dL)

          -  History of cancer

          -  Autoimmune disorder or HIV+ status

          -  Use of nicotine products

          -  Have any other history of major medical illness, disease or other relevant orthopaedic
             disability

          -  Who do not speak English

          -  Liodcaine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Mendias, PhD, ATC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Rodeo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Edon, MS, CSCS</last_name>
    <phone>212-774-7833</phone>
    <email>EdonD@hss.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Edon, MS, CSCS</last_name>
      <phone>212-774-7833</phone>
      <email>EdonD@hss.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bridget Hayes, MS</last_name>
      <phone>212-774-7154</phone>
      <email>Hayesb@hss.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher L Mendias, PhD, ATC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bedi A, Dines J, Warren RF, Dines DM. Massive tears of the rotator cuff. J Bone Joint Surg Am. 2010 Aug 4;92(9):1894-908. doi: 10.2106/JBJS.I.01531. Review.</citation>
    <PMID>20686065</PMID>
  </reference>
  <reference>
    <citation>Mendias CL, Roche SM, Harning JA, Davis ME, Lynch EB, Sibilsky Enselman ER, Jacobson JA, Claflin DR, Calve S, Bedi A. Reduced muscle fiber force production and disrupted myofibril architecture in patients with chronic rotator cuff tears. J Shoulder Elbow Surg. 2015 Jan;24(1):111-9. doi: 10.1016/j.jse.2014.06.037. Epub 2014 Sep 3.</citation>
    <PMID>25193488</PMID>
  </reference>
  <reference>
    <citation>Davis ME, Stafford PL, Jergenson MJ, Bedi A, Mendias CL. Muscle fibers are injured at the time of acute and chronic rotator cuff repair. Clin Orthop Relat Res. 2015 Jan;473(1):226-32. doi: 10.1007/s11999-014-3860-y. Epub 2014 Aug 12.</citation>
    <PMID>25113269</PMID>
  </reference>
  <reference>
    <citation>Gumucio JP, Flood MD, Roche SM, Sugg KB, Momoh AO, Kosnik PE, Bedi A, Mendias CL. Stromal vascular stem cell treatment decreases muscle fibrosis following chronic rotator cuff tear. Int Orthop. 2016 Apr;40(4):759-64. doi: 10.1007/s00264-015-2937-x. Epub 2015 Jul 30.</citation>
    <PMID>26224616</PMID>
  </reference>
  <reference>
    <citation>Gumucio JP, Davis ME, Bradley JR, Stafford PL, Schiffman CJ, Lynch EB, Claflin DR, Bedi A, Mendias CL. Rotator cuff tear reduces muscle fiber specific force production and induces macrophage accumulation and autophagy. J Orthop Res. 2012 Dec;30(12):1963-70. doi: 10.1002/jor.22168. Epub 2012 Jun 13.</citation>
    <PMID>22696414</PMID>
  </reference>
  <reference>
    <citation>Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, Redl H, Rubin JP, Yoshimura K, Gimble JM. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013 Jun;15(6):641-8. doi: 10.1016/j.jcyt.2013.02.006. Epub 2013 Apr 6.</citation>
    <PMID>23570660</PMID>
  </reference>
  <reference>
    <citation>Doi K, Tanaka S, Iida H, Eto H, Kato H, Aoi N, Kuno S, Hirohi T, Yoshimura K. Stromal vascular fraction isolated from lipo-aspirates using an automated processing system: bench and bed analysis. J Tissue Eng Regen Med. 2013 Nov;7(11):864-70. doi: 10.1002/term.1478. Epub 2012 Mar 22.</citation>
    <PMID>22438241</PMID>
  </reference>
  <reference>
    <citation>Williams SK, Kosnik PE, Kleinert LB, Vossman EM, Lye KD, Shine MH. Adipose stromal vascular fraction cells isolated using an automated point of care system improve the patency of expanded polytetrafluoroethylene vascular grafts. Tissue Eng Part A. 2013 Jun;19(11-12):1295-302. doi: 10.1089/ten.TEA.2012.0318. Epub 2013 Mar 15.</citation>
    <PMID>23350681</PMID>
  </reference>
  <reference>
    <citation>Hernigou P, Flouzat Lachaniette CH, Delambre J, Zilber S, Duffiet P, Chevallier N, Rouard H. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. Int Orthop. 2014 Sep;38(9):1811-8. doi: 10.1007/s00264-014-2391-1. Epub 2014 Jun 7.</citation>
    <PMID>24913770</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

